PLoS ONE (Nov 2010)

Serum neurotrophin profile in systemic sclerosis.

  • Marie-Claude Lise,
  • Agnès Sparsa,
  • Isabelle Marie,
  • Fabrice Lalloué,
  • Kim Ly,
  • Clothilde Martel,
  • Holy Bezanahary,
  • Guillaume Gondran,
  • Véronique Loustaud-Ratti,
  • Jean-Marie Bonnetblanc,
  • Elisabeth Vidal,
  • Marie-Odile Jauberteau,
  • Anne-Laure Fauchais

DOI
https://doi.org/10.1371/journal.pone.0013918
Journal volume & issue
Vol. 5, no. 11
p. e13918

Abstract

Read online

BackgroundNeurotrophins (NTs) are able to activate lymphocytes and fibroblasts; they can modulate angiogenesis and sympathic vascular function. Thus, they can be implicated in the three pathogenic processes of systemic sclerosis (SSc). The aims of this study are to determine blood levels of Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) in SSc and to correlate them with clinical and biological data.MethodsSerum samples were obtained from 55 SSc patients and 32 control subjects to measure NTs levels by ELISA and to determine their relationships with SSc profiles.FindingsSerum NGF levels were higher in SSc patients (288.26 ± 170.34 pg/mL) than in control subjects (170.34 ± 50.8 pg/mL, pConclusionLow BDNF serum levels were not previously documented in SSc, particularly in the diffuse SSc subset and in patients with pulmonary hypertension or anti-Scl-70 antibodies. The negative correlation between NGF and BDNF levels observed in SSc and not in healthy controls could be implicated in sympathic vascular dysfunction in SSc.